Capstone Investment Advisors
RXRX icon

Capstone Investment Advisors’s Recursion Pharmaceuticals RXRX Stock Holding History

Capstone Investment Advisors’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$816K Buy
222,378
+175,897
+378% +$586K ﹤0.01% 1028
2026
Q1 		$143K Buy
+46,481
New +$180K ﹤0.01% 1539
2025
Q3 		– Sell
-40,303
Closed -$204K – 2043
2025
Q2 		$204K Buy
+40,303
New +$198K ﹤0.01% 1527
2024
Q2 		– Sell
-16,100
Closed -$161K – 2412
2024
Q1 		$161K Buy
+16,100
New +$179K ﹤0.01% 2059

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Capstone Investment Advisors's RXRX Position: Q2 2026 in Review

Capstone Investment Advisors increased its Recursion Pharmaceuticals (RXRX) stake by 378% in Q2 2026, buying an estimated $586K and bringing the position to 222,378 shares worth $816K. The position accounts for ﹤0.01% of the portfolio, ranked #1028.

Capstone Investment Advisors first reported a position in RXRX in Q1 2024 and has held it in 4 quarters since. 343 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • Capstone Investment Advisors held 222,378 shares of Recursion Pharmaceuticals worth $816K as of Q2 2026.
  • Capstone Investment Advisors bought 175,897 Recursion Pharmaceuticals shares in Q2 2026, an estimated $586K.
  • Recursion Pharmaceuticals made up ﹤0.01% of Capstone Investment Advisors's portfolio in Q2 2026, its #1028 holding.
  • Capstone Investment Advisors first reported a position in Recursion Pharmaceuticals in Q1 2024 and has held it in 4 quarters since.
  • 343 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Capstone Investment Advisors's 13F filing for Q2 2026, filed 17 Aug 2026.